Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
umbilical cord mesenchymal stem cells + autologous bone marrow mononuclear cells
- Development stage
- Unknown
- Lead developer
- 900th Hospital of Joint Logistics Support Force of PLA
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intra-arterial
01
Overview
This experimental cell therapy, developed by Fuzhou General Hospital, is a combination treatment consisting of umbilical cord-derived mesenchymal stem cells (UC-MSCs) and autologous bone marrow mononuclear cells (aBM-MNCs). Investigated primarily for the treatment of type 1 diabetes mellitus, the therapy is administered via supraselective pancreatic artery cannulation. The mechanism of action involves the immunomodulatory properties of UC-MSCs and the regenerative potential of both cell types to preserve residual beta-cell function and promote the regeneration of insulin-secreting cells. Clinical study results have indicated that the treatment is well-tolerated and can lead to improved C-peptide levels and glycemic control in responders without the need for traditional immunotherapy.
- Other names
- Umbilical mesenchymal stem cell-Fuzhou General Hospital-type 1 diabetes mellitusUC-MSCs and Mononuclear Cells InfusionUC-MSC + aBM-MNC
Beyond the preview
Go deeper on umbilical cord mesenchymal stem cells + autologous bone marrow mononuclear cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on umbilical cord mesenchymal stem cells + autologous bone marrow mononuclear cells.